Trovagene (TROV) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. ZETA
10. DAL

Go back to Trovagene (TROV) Misses Q1 EPS by 8c

Trovagene Announces First Quarter 2017 Company Highlights and Financial Results

May 10, 2017 4:05 PM EDT

SAN DIEGO, May 10, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2017. 

"We are excited about the advancement of our business in precision medicine and the development of precision cancer therapeutics for improved cancer care. This includes the licensing and progress in our clinical development plans for PCM-075, our investigational, oral and highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML)," said... More